Tecogen (Tecogen) ROCE % : -39.53% (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Tecogen ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Tecogen's annualized ROCE % for the quarter that ended in Dec. 2023 was -39.53%.

Tecogen ROCE % Historical Data

The historical data trend for Tecogen's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tecogen ROCE % Chart

Tecogen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-14.53

-24.95

17.08

-10.56

-23.31

Tecogen Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-26.47	-29.40	-15.47	-8.80	-39.53

Tecogen ROCE % Calculation

Tecogen's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-4.414	/	( ( (28.253 - 7.686)	+	(27.793 - 10.483) )	/ 2 )
	=	-4.414	/	( (20.567	+	17.31)	/ 2 )
	=	-4.414	/	18.9385
	=	-23.31 %

Tecogen's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-7.188	/	( ( (29.187 - 10.127)	+	(27.793 - 10.483) )	/ 2 )
	=	-7.188	/	( ( 19.06	+	17.31 )	/ 2 )
	=	-7.188	/	18.185
	=	-39.53 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Tecogen (OTCPK:TGEN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Tecogen ROCE % Related Terms

Thank you for viewing the detailed overview of Tecogen's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Tecogen (Tecogen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Industrials » Industrial Products » Tecogen Inc (OTCPK:TGEN) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

2T1:Germany

Address

45 First Avenue, Waltham, MA, USA, 02451

Website

https://www.tecogen.com

Tecogen Inc, designs, manufactures, markets, and maintains high efficiency, ultra-clean cogeneration products. It operates in three business segments, namely Products, Services and Energy Production. Products segment designs, manufactures and sells industrial and commercial cogeneration systems. Services segment provides operations and maintenance services and turn-key installation for products under long term service contracts. Energy Production segment sells energy in the form of electricity, heat, hot water and cooling to the customers under long-term energy sales agreements.

Executives

Earl R Lewis	director	C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843
John Hatsopoulos	director, 10 percent owner, officer: Chief Executive Officer	85 FIRST AVENUE, WALTHAM MA 02451
Susan B Hirsch	director	280 OLD SOMERSET ROAD, WATCHUNG NJ 07069
Abinand Rangesh	director, officer: Chief Financial Officer	45 FIRST AVE, WALTHAM MA 02451
John M Albertine	director	100 FEDERAL DRIVE, FREDERICKSBURG VA 22405
Pacheco Ann Marie Brown	10 percent owner, other: Trustee	C/O TECOGEN INC., 45 FIRST AVE., WALTHAM MA 02451
Ralph Jenkins	director	45 FIRST AVE, WALTHAM MA 02451
Fred Holubow	director
Locke M. Benjamin	officer: Co-CEO	45 FIRST AVE, WALTHAM MA 02451
Whiting John Kimball Iv	officer: General Counsel & Secretary	49 L STREET, UNIT 9, BOSTON MA 02127
Deanna M Petersen	director	45 FIRST AVENUE, WALTHAM MA 02451
Yiannis Monovoukas	10 percent owner	TEI BIOSCIENCES, INC., 7 ELKINS STREET, BOSTON MA 02127
Charlest Maxwell	director	6100 NORTH WESTERN AVE, OKLAHOMA CITY OK 73118
Keith Davidson	director	C/O TECOGEN INC., 45 FIRST AVE., WALTHAM MA 02451
David A Garrison	officer: CFO, Treasurer and Secretary	C/O ARRHYTHMIA RESEARCH TECHNOLOGY INC., 25 SAWYER PASSWAY, FITCHBURG MA 01420